0.8548
price down icon2.43%   -0.0213
after-market Handel nachbörslich: .85 -0.0048 -0.56%
loading
Schlusskurs vom Vortag:
$0.8761
Offen:
$0.8603
24-Stunden-Volumen:
169.48K
Relative Volume:
0.99
Marktkapitalisierung:
$61.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.52M
KGV:
-0.4802
EPS:
-1.78
Netto-Cashflow:
$-107.56M
1W Leistung:
-0.73%
1M Leistung:
-3.54%
6M Leistung:
-28.17%
1J Leistung:
-77.45%
1-Tages-Spanne:
Value
$0.7796
$0.887
1-Wochen-Bereich:
Value
$0.7796
$0.9485
52-Wochen-Spanne:
Value
$0.6101
$6.80

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Name
Firmenname
Prelude Therapeutics Inc
Name
Telefon
(302) 467-1280
Name
Adresse
175 INNOVATION BOULEVARD, WILMINGTON
Name
Mitarbeiter
131
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
PRLD's Discussions on Twitter

Vergleichen Sie PRLD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PRLD
Prelude Therapeutics Inc
0.8548 61.82M 0 -131.52M -107.56M -1.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.82 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
520.29 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.94 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.53 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
267.12 28.51B 3.81B -644.79M -669.77M -6.24

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-09-19 Hochstufung H.C. Wainwright Neutral → Buy
2024-06-20 Herabstufung Barclays Equal Weight → Underweight
2024-03-13 Eingeleitet JMP Securities Mkt Outperform
2024-02-20 Herabstufung H.C. Wainwright Buy → Neutral
2023-12-19 Herabstufung Morgan Stanley Equal-Weight → Underweight
2022-11-21 Herabstufung BofA Securities Neutral → Underperform
2022-09-09 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-07-29 Eingeleitet Jefferies Buy
2022-03-15 Herabstufung BofA Securities Buy → Neutral
2022-02-28 Herabstufung Barclays Overweight → Equal Weight
2021-10-08 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-07-27 Hochstufung BofA Securities Neutral → Buy
2021-04-26 Eingeleitet H.C. Wainwright Buy
2021-03-09 Eingeleitet Barclays Overweight
2020-11-20 Herabstufung BofA Securities Buy → Neutral
2020-10-20 Eingeleitet BofA Securities Buy
2020-10-20 Eingeleitet Goldman Neutral
2020-10-20 Eingeleitet Morgan Stanley Equal-Weight
Alle ansehen

Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten

pulisher
Jun 17, 2025

Baker Bros. Advisors LP Increases Stake in Prelude Therapeutics Inc. - GuruFocus

Jun 17, 2025
pulisher
Jun 11, 2025

Two Sigma Investments LP Purchases 174,906 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Jun 11, 2025
pulisher
Jun 08, 2025

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Acquired by Millennium Management LLC - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

20,572 Shares in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Purchased by BNP Paribas Financial Markets - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Two Sigma Advisers LP Raises Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

Prelude Therapeutics describes new SMARCA2 and SMARCA4 degradation inducers - BioWorld MedTech

Jun 04, 2025
pulisher
Jun 04, 2025

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Northern Trust Corp - Defense World

Jun 04, 2025
pulisher
Jun 02, 2025

Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025 - MyChesCo

Jun 02, 2025
pulisher
Jun 02, 2025

Prelude Therapeutics to Participate in Upcoming Healthcare Confe - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences | PRLD Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Precision Oncology Pioneer Prelude Therapeutics Sets Stage for Major June Healthcare Conference Updates - Stock Titan

Jun 02, 2025
pulisher
Jun 02, 2025

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences - Yahoo Finance

Jun 02, 2025
pulisher
May 28, 2025

Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 28, 2025
pulisher
May 27, 2025

Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges - Investing.com India

May 27, 2025
pulisher
May 22, 2025

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal - insights.citeline.com

May 22, 2025
pulisher
May 15, 2025

AI-powered drug development startup Pathos AI closes $365M investment - SiliconANGLE

May 15, 2025
pulisher
May 15, 2025

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug - Fierce Biotech

May 15, 2025
pulisher
May 11, 2025

Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MyChesCo

May 11, 2025
pulisher
May 11, 2025

Mineralys Therapeutics to Present at Bank of America Health Care Conference - MyChesCo

May 11, 2025
pulisher
May 10, 2025

Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs - MyChesCo

May 10, 2025
pulisher
May 10, 2025

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Price T Rowe Associates Inc. MD - The AM Reporter

May 10, 2025
pulisher
May 10, 2025

What is HC Wainwright’s Estimate for PRLD Q2 Earnings? - Defense World

May 10, 2025
pulisher
May 09, 2025

SEED Therapeutics Unveils Groundbreaking Advances in Cancer Research at AACR 2025 - MyChesCo

May 09, 2025
pulisher
May 09, 2025

Q1 Earnings Forecast for PRLD Issued By HC Wainwright - Defense World

May 09, 2025
pulisher
May 08, 2025

Prelude Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 08, 2025
pulisher
May 07, 2025

JPMorgan Chase & Co. Purchases 55,183 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

May 07, 2025
pulisher
May 06, 2025

Prelude Therapeutics (NASDAQ:PRLD) Given Buy Rating at HC Wainwright - Defense World

May 06, 2025
pulisher
May 06, 2025

Prelude Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 06, 2025
pulisher
May 06, 2025

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 06, 2025
pulisher
May 05, 2025

Prelude Therapeutics (PRLD) Rating Reiterated with $5 Target by HC Wainwright | PRLD Stock News - GuruFocus

May 05, 2025
pulisher
May 04, 2025

Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025 - MyChesCo

May 04, 2025
pulisher
May 04, 2025

Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday - Defense World

May 04, 2025
pulisher
May 02, 2025

Prelude Therapeutics Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView

May 02, 2025
pulisher
May 02, 2025

Renaissance Technologies LLC Increases Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

May 02, 2025
pulisher
May 01, 2025

Prelude Therapeutics to Participate in Citizens Life Sciences Conference - Bluefield Daily Telegraph

May 01, 2025
pulisher
May 01, 2025

Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MyChesCo

May 01, 2025
pulisher
May 01, 2025

JMP Securities Reaffirms Market Outperform Rating for Prelude Therapeutics (NASDAQ:PRLD) - Defense World

May 01, 2025
pulisher
Apr 29, 2025

Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies - MSN

Apr 29, 2025
pulisher
Apr 29, 2025

JMP maintains $4 target on Prelude Therapeutics stock By Investing.com - Investing.com Canada

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting - MyChesCo

Apr 29, 2025
pulisher
Apr 25, 2025

Prelude Announces Presentations at 2025 AACR Annual Meeting | PR - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Prelude Therapeutics Presents Preclinical Data on First-in-Class SMARCA2 and Selective KAT6A Degraders at AACR Annual Meeting - Nasdaq

Apr 25, 2025
pulisher
Apr 25, 2025

Prelude Announces Presentations at 2025 AACR Annual Meeting - Yahoo Finance

Apr 25, 2025
pulisher
Apr 23, 2025

Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MyChesCo

Apr 23, 2025
pulisher
Apr 17, 2025

Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MyChesCo

Apr 17, 2025
pulisher
Apr 11, 2025

HC Wainwright Issues Positive Forecast for PRLD Earnings - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know - MSN

Apr 10, 2025
pulisher
Apr 07, 2025

PRLD stock touches 52-week low at $0.61 amid market challenges - Investing.com

Apr 07, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Context Therapeutics Announces Participation in Key Investor Conferences - MyChesCo

Apr 02, 2025
pulisher
Apr 02, 2025

Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo

Apr 02, 2025

Finanzdaten der Prelude Therapeutics Inc-Aktie (PRLD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Prelude Therapeutics Inc-Aktie (PRLD) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Vaddi Krishna
CEO
Mar 25 '25
Buy
0.69
675,000
467,438
1,999,296
Vaddi Krishna
CEO
Mar 21 '25
Buy
0.73
15,000
10,959
1,324,296
Vaddi Krishna
CEO
Mar 20 '25
Buy
0.73
5,416
3,950
1,309,296
Vaddi Krishna
CEO
Mar 14 '25
Buy
0.75
29,999
22,631
1,294,774
Vaddi Krishna
CEO
Mar 17 '25
Buy
0.75
9,106
6,829
1,303,880
Vaddi Krishna
CEO
Mar 13 '25
Buy
0.72
50,000
35,820
1,264,775
Vaddi Krishna
CEO
Mar 12 '25
Buy
0.71
47,500
33,744
1,214,775
Vaddi Krishna
CEO
Dec 31 '24
Buy
1.21
5,000
6,044
142,553
Vaddi Krishna
CEO
Dec 30 '24
Buy
1.20
10,000
12,000
137,553
Combs Andrew
Chief Chemistry Officer
Dec 23 '24
Buy
1.37
60,000
82,002
377,623
$20.52
price down icon 1.06%
$35.91
price down icon 0.64%
$21.27
price up icon 1.67%
$104.85
price down icon 0.99%
$104.80
price down icon 0.28%
biotechnology ONC
$267.12
price up icon 0.12%
Kapitalisierung:     |  Volumen (24h):